📚 Lecture Overview
Rheumatoid arthritis (RA) is a chronic, inflammatory, progressive autoimmune disease characterized by symmetric inflammatory polyarthritis and extra-articular multisystem involvement. Understanding its pathogenesis, clinical presentation, and early aggressive management strategy is essential for preventing irreversible joint destruction and disability.
🎯 Key Concepts & Definitions
- Rheumatoid Arthritis (RA): A chronic inflammatory progressive autoimmune disease with symmetric inflammatory polyarthritis and extra-articular multisystem involvement.
- Pannus: Inflammatory granulation tissue spreading over and under the articular cartilage, leading to cartilage erosion and joint destruction.
- ACPA / Anti-CCP: Anti-citrullinated protein antibodies; highly specific diagnostic and prognostic markers for RA.
- Rheumatoid Factor (RF): An antiglobulin antibody (commonly IgM) directed against the Fc fragment of IgG; sensitive but less specific than anti-CCP.
- LORA: Late-onset rheumatoid arthritis, defined as RA presenting after the age of 60–65.
- Caplan's Syndrome: The combination of rheumatoid nodules and pneumoconiosis in patients with RA exposure to dust.
- Baker's Cyst: Accumulation of excess synovial fluid in the popliteal fossa due to a one-way valve effect, which can rupture and mimic deep vein thrombosis (DVT).
- DMARDs: Disease-Modifying Anti-Rheumatic Drugs used to decrease inflammatory synovitis and retard joint destruction.
📖 Main Content
Epidemiology and Etiology
- Affects 0.5–1% of European and North American adults.
- Women are affected about three times more frequently than men, with a peak age of incidence between 45 and 60 years.
- First-degree relatives have a 2–10 times higher risk of developing RA.
- Genetic Risk: Strongly associated with HLA-DR1, DR4, and DRW14, featuring a shared epitope on the beta chain.
- Environmental Risk: Cigarette smoking is the single most important environmental risk factor, promoting enhanced protein citrullination in the lungs.
Pathology and Pathogenesis
- Synovial membrane undergoes infiltration with Th1 lymphocytes, macrophages, and plasma cells.
- Synovial hypertrophy leads to villous formation and lymphoid follicle development.
- Formation of pannus results in articular cartilage erosion, adjacent muscle atrophy, and soft tissue destruction leading to laxity and deformities.
- Progression can result in fibrous and bony ankylosis.
Clinical Features: Articular Manifestations
- Inflammatory Joint Pain: Increases with rest, decreases with movement, accompanied by swelling, tenderness, and warmth.
- Morning Stiffness: Lasts for more than 30 minutes due to inflammatory mediator accumulation during inactivity.
- Symmetric Polyarthritis Pattern:
- Commonly affects wrists, MCPs, PIPs, elbows, feet, ankles, and knees.
- DIP sparing is characteristic.
- Spinal involvement is limited to the upper cervical spine; sacroiliac joints are spared.
- Hand Deformities:
- Ulnar deviation at the MCP joint.
- Swan Neck Deformity: Hyperextension at PIP with flexion at DIP.
- Boutonniere Deformity: Flexion at the PIP with extension at DIP.
- Z-shaped deformity of the thumb.
Clinical Features: Extra-Articular Manifestations
- Rheumatoid Nodules: Found in ~25% of patients, almost exclusively in seropositive individuals. Typically firm, non-tender, mobile, and located on extensor surfaces (e.g., forearms, elbows). Methotrexate therapy can paradoxically trigger increased nodulosis.
- Rheumatoid Vasculitis: Seen in severe, long-standing disease; manifests as nailfold infarcts, palpable purpura, or mononeuritis multiplex.
- Ocular: Sjogren's syndrome (dry eyes), episcleritis, painful scleritis, and corneal melting.
- Respiratory: Interstitial fibrosis (most common pulmonary manifestation, in lower lobes), pleural effusion (low glucose, high LDH), and Caplan's syndrome.
- Neurological: Carpal tunnel syndrome (median nerve entrapment) and cervical cord compression due to atlantoaxial subluxation (distance between odontoid peg and atlas > 3 mm on flexed lateral X-ray).
Diagnosis and Investigation
- Rheumatoid Factor (RF): Positive in ~85% of patients (70% early on); lacks prognostic significance and can be positive in chronic infections, liver disease, and Sjögren's.
- Anti-CCP Antibodies: High specificity (~98%) and serve as predictors of disease severity; detectable in the preclinical phase.
- Acute Phase Reactants: Elevated ESR and CRP reflect systemic inflammation.
- Imaging:
- Plain X-rays show periarticular osteopenia, joint space narrowing, and erosions.
- MSUS (Musculoskeletal Ultrasound) detects early synovitis, erosions, and increased blood flow via power Doppler earlier than X-rays.
Treatment Strategy
- Goal: Early diagnosis and aggressive treatment within 12 weeks of onset to prevent joint destruction occurring in the first 2 years.
- NSAIDs: Control pain and inflammation but do not prevent structural damage. Associated with GI toxicity, renal impairment, and fluid retention.
- Corticosteroids: Provide rapid anti-inflammatory action; used as bridge therapy (short-term, lowest dose like 7.5 mg) or for extra-articular manifestations.
- Conventional DMARDs (csDMARDs): Methotrexate is the anchor drug; others include Leflunomide, Hydroxychloroquine, and Sulfasalazine.
- Targeted Synthetic DMARDs (tsDMARDs): JAK inhibitors (Baricitinib, Tofacitinib, Upadacitinib) block intracellular kinases.
- Biological DMARDs (boDMARDs):
- Anti-TNF agents (Infliximab) — screen for latent TB with PPD/IGRA before starting.
- T-cell co-stimulation blocker (Abatacept).
- Anti-CD20 B-cell depleter (Rituximab).
- IL-6 receptor inhibitor (Tocilizumab) — improves anemia by suppressing hepcidin.
📊 Visual Learning
flowchart TD
A["Genetic Susceptibility"] --> B["Environmental Triggers"]
B --> C["Protein Citrullination"]
C --> D["ACPA Formation"]
D --> E["Synovial Inflammation"]
E --> F["Pannus Formation"]
F --> G["Joint Destruction"]
flowchart LR
A["Initial Presentation"] --> B["Start csDMARDs"]
B --> C{"Incomplete Response"}
C -->|Yes| D["Add tsDMARD or biologic"]
C -->|No| E["Maintain and Taper"]
mindmap
root("RA Extra-Articular Features")
"Nodules"
"Extensor surfaces"
"Assoc with RF"
"Vasculitis"
"Nailfold infarcts"
"Purpura"
"Ocular"
"Scleritis"
"Sjogren syndrome"
"Pulmonary"
"Interstitial fibrosis"
"Caplans syndrome"
💡 Important Points to Remember
- DIP joints are spared in rheumatoid arthritis, unlike osteoarthritis.
- Cigarette smoking is the primary environmental risk factor, driving protein citrullination in the lungs.
- Anti-CCP antibodies have high specificity (~98%) and predict severe disease progression.
- Methotrexate is the cornerstone (anchor) conventional DMARD.
- Methotrexate toxicity can paradoxically cause accelerated subcutaneous rheumatoid nodulosis.
- Latent TB screening (PPD or IGRA) is mandatory before starting anti-TNF biological therapy.
- Cricoarytenoid joint involvement causes laryngeal pain, dysphonia, and pain on swallowing.
- Atlantoaxial subluxation risks cervical cord compression; diagnosed if the distance between the odontoid peg and atlas is > 3 mm on a flexed lateral X-ray.
- Tocilizumab uniquely improves anemia of chronic disease by inhibiting IL-6-induced hepcidin production.
- Baker's cyst rupture in the calf can clinically mimic deep vein thrombosis (DVT).
⚠️ Common Exam Questions & Traps
- MCQ Trap: Examiners often include joint distribution options featuring DIP joint involvement to trick students. Remember: RA spares the DIP joints and the sacroiliac joints (except upper cervical spine).
- Matching Trap: Confusing RF and Anti-CCP specificity. RF is sensitive (~85%) but lacks high specificity and prognostic value, whereas Anti-CCP has high specificity (~98%) and correlates with severe disease.
- Pharmacology Trap: Forgetting mandatory latent TB screening prior to prescribing anti-TNF biologics (like Infliximab), which can reactivate latent tuberculosis.
- Clinical Scenario: A patient on methotrexate develops worsening subcutaneous nodules on the elbows. Examiners may ask if this means treatment failure; the correct concept is that methotrexate can induce accelerated nodulosis despite controlling joint disease.
📝 Quick Review Checklist
I can define rheumatoid arthritis and state its epidemiological profile
I understand the genetic (HLA-DR4, shared epitope) and environmental (smoking) risk factors
I can describe the formation of pannus and its impact on articular cartilage
I can distinguish articular hand deformities (Swan Neck vs. Boutonniere)
I know the key differences between RF and Anti-CCP antibodies
I can recognize extra-articular manifestations including rheumatoid nodules and pulmonary fibrosis
I understand the diagnostic criteria and imaging findings (MSUS vs. X-ray)
I know the treatment algorithm starting with csDMARDs and progressing to biologics/JAK inhibitors